Obtain preliminary preclinical study results for the SB019 COVID-19 program
Delivered by the deadline
AI-assessed · human review in progress Found and assessed by AI from the cited sources. Shown with its evidence; it is not counted in any Kept Score until confirmed.
- Announced
- 25 Feb 2021
- Due
- 30 Jun 2021
- Delivered
- 10 Jun 2021
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Advancing this program through preliminary preclinical studies, which Novan targets to have results in the second quarter of 2021;”
What we found
Evidence strength A What the grades mean
Novan announced positive preliminary in vivo preclinical results for berdazimer sodium as an intranasal COVID-19 option on June 10, 2021, before the June 30, 2021 deadline.
-
A Novan, Inc. 10-Q filed 2021-08-12
“On June 10, 2021, we announced positive results from two separate studies that independently demonstrated the ability of berdazimer sodium to prevent progression of infection into the lungs after transmission” ✓ confirmed on the page
-
A Novan, Inc. 8-K filed 2021-09-09
“To evaluate SB019 as a potential intranasal treatment option for COVID-19, the Company completed preclinical in vivo studies evaluating the effect of berdazimer sodium to reduce viral load in infected animals” ✓ confirmed on the page
Checked 26 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical readout
- Indicative materiality
- Medium rules
- Action
- Obtain
- Deliverable
- Preliminary preclinical study results for SB019
- Language
- Aspirational (“aims”, “intends”)
- In the company’s control
- High
- Specificity
- Medium
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Claude (Anthropic), read the company's later filings and recorded the outcome with a quoted passage.
Not yet confirmed. Shown on the record, but it will not count in any score until it is confirmed. How verification works
Are you Novan, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-C467154-024556 · Corrections policy